Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery in Focus ...
Published . Updated .
Dr Reddy's Laboratories Ltd (RDY) posted a 1.5% YoY revenue dip on lower lenalidomide sales but guided to improving gross margins, a November 2026 semaglutide relaunch and a December abatacept PDUFA.
Directly affected
- No company is named in this report.
Indirectly affected
- No related companies are mapped for this report yet.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery in Focus ... Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| GLD | three days earlier | +3.37% | final price |
| GLD | five days earlier | +3.56% | final price |
| QQQ | three days earlier | +2.99% | final price |
| QQQ | five days earlier | +2.00% | final price |
| SPY | three days earlier | +1.75% | final price |
| SPY | five days earlier | +0.89% | final price |
| TLT | three days earlier | -1.35% | final price |
| TLT | five days earlier | -2.31% | final price |
This story
12 out of 100
“Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery in Focus ...” scores 12 out of 100. The score uses 1 sources.